Tissue factor pathway inhibitor and anitithrombin trial results

Critical Care Clinics

Volumn 21, Issue 3 SPEC. ISS., 2005, Pages 433-448

  LaRosa, Steven P ^a,c   Opal, Steven M ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; DROTRECOGIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; RECOMBINANT ANTITHROMBIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SYNDECAN 4; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENDOTOXEMIA; HUMAN; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS; MORTALITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE;

EID: 21244438366     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2005.02.002     Document Type: Review

References (69)

1. M.G. Vervloet, L.G. Thijs, and C.E. Hack Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock Semin Thromb Hemost 24 1998 33 44
2. M.P. Bevilacqua, J.S. Pober, and G.R. Majeau Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with actions of interleukin1 Proc Natl Acad Sci USA 83 1986 4533 4537
3. E. Abraham, K. Reinhart, and S. Opal Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis JAMA 290 2003 238 247
4. nd annual meeting Infectious Disease Society of America. Boston: 2004. p. 76
5. A. Creasey New potential therapeutic modalities: tissue factor pathway inhibitor Sepsis 3 1999 173 182
6. M. Riewald, and W. Ruf Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor Proc Natl Acad Sci USA 98 14 2001 7742 7747
7. N.H.M. Senden, T.M.A.A. Jeunhomme, and J.W.M. Heemserk Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells J Immunol 161 1998 4318 4324
8. P. Schaeffer, A.M. Mares, and F. Dol Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta Circ Res 81 1997 824 828
9. P. Enkhbaatar, K. Okajima, and K. Murakami Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation Am J Respir Crit Care Med 162 2000 1752 1759
10. A.A. Creasey, A.C.K. Chang, and L. Feigen Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock J Clin Invest 91 1993 2850 2860
11. R. Maytal, Y. Vin, and R.L. Delude Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock Intensive Care Med 27 2001 1274 1280
12. C.T. Park, A.A. Creasey, and S.D. Wright Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14 Blood 89 12 1997 4268 4274
13. P.M. Jensen, T. van Lopik, and Y. Lubbers The coagulant-inflammatory axis in the baboon response to E. coli: effects of tissue factor pathway inhibitor on haemostatic balance, the cytokine network and release of the apoptosis marker sFas C.E. Hack Inflammatory markers in primate sepsis 1997 University of Amsterdam Amsterdam 95 107
14. A. Creasey, and K. Reinhart Tissue factor pathway inhibitor activity in severe sepsis Crit Care Med 29 Suppl 2001 S126 S129
15. S. Gando, T. Kameue, and N. Matsuda Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients Thromb Res 109 2-3 2003 119 124
16. S. Gando, T. Kameue, and Y. Morimoto Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis Crit Care Med 30 2002 1729 1734
17. M. Eling, A.C. Stephens, and E.E. Oragui Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease Thromb Haemost 85 2001 240 244
18. T. Shimokawa, K. Yamamoto, T. Kojima, and H. Saito Down - regulation of murine tissue factor pathway inhibitor mRNA by endotoxin and tumor necrosis factor-alpha in vitro and in vivo Thromb Res 100 2000 211 221
19. E. Abraham, K. Reinhart, and P. Svoboda Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single blind, dose-escalation study Crit Care Med 29 11 2001 2081 2089
20. E. de Jonge, P.E.P. Dekkers, and A.A. Creasey Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia Blood 95 4 2000 1124 1129
21. E. de Jonge, P.E.P. Dekkers, and A.A. Creasey Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia J Infect Dis 183 2001 1815 1818
22. K. Enjyoji, T. Miyata, and Y. Kamikubo Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment Gly212-Phe243, of the third Kunitz domain is a heparin-binding site Biochemistry 34 1995 5725 5735
23. J.B. Hansen, and P.M. Sandset Differential effects of low molecular weight and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy Thromb Res 91 1998 177 181
24. M.J.B. Kemme, J. Burggraaf, and C. Rik Quantification of heparin-induced TFPI release: a maximum release at low heparin dose Br J Clin Pharmacol 54 2002 627 634
25. S.M. Opal, J.P. Scannon, and J.L. Vincent Relationship between plasma levels of lipopolysaccharide (LPS) and LBP-binding protein in patients with severe sepsis and septic shock J Infect Dis 180 5 1999 1584 1589
26. S.M. Opal, G.E. Garber, and S.P. LaRosa Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated) Clin Infect Dis 37 2003 50 58
27. J.F. Dhainaut, P.F. Laterre, and S.P. LaRosa The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology and results Crit Care Med 31 2003 2291 2301
28. T.J. Gross, R.H. Simon, and R.G. Sitrin Tissue factor procoagulant expression by rat alveolar epithelial cells Am J Repir Cell Mol Biol 6 4 1992 397 403
29. M.P. McGee, R. Wallin, F.B. Wheeler, and H. Rothberger Initiation of the extrinsic pathway of coagulation by human and rabbit alveolar macrophages: a kinetic study Blood 74 5 1989 1583 1590
30. A. Gunther, P. Monsavi, and S. Heinemann Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia; comparison with the acute respiratory distress syndrome Am J Respir Crit Care Med 161 2000 454 462
31. M. Levi, M.J. Schultz, A.W. Rijneveld, and T. van der Poll Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia Crit Care Med 31 Suppl. 2003 S238 S242
32. M. Schultz, J. Milo, and M. Levi Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator-associated pneumonia Am J Respir Crit Care Med 167 7 2003 A861
33. H.G. Schipper, L.H. Kahle, C.S.P. Jenkins, and J.W. Ten Care Antithrombin III transfusion in disseminated intravascular coagulation Lancet II 1978 854 856
34. J.J. Corrigan, and C.M. Jordan Heparin therapy in septicemia with disseminated intravascular coagulation N Engl J Med 15 1970 778 782
35. J.J. Corrigan Heparin therapy in bacterial septicaemia J Ped 91 1977 695 700
36. S.M. Opal Therapeutic rationale for antithrombin in sepsis Crit Care Med 28 2000 S34 S37
37. B. Blauhut, H. Kramar, H. Vinazzer, and H. Bergmann Substitution of antithrombin III in shock and DIC: a randomized study Thromb Res 39 1985 81 89
38. F.B. Taylor Jr, R.E. Emerson Jr, R. Jordan, A.K. Chang, and K.E. Blick Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons Circ Shock 26 1988 227 235
39. T.E. Emerson Jr, M.A. Fournel, T.B. Redens, and F.B. Taylor Jr Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia Am J Med 87 3B 1989 27S 33S
40. G. Dickneite, and E.P. Paques Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis Thromb Haemost 69 1993 98 102
41. G. Dickneite Antithrombin III in animal models of sepsis and organ failure Semin Thromb Haemost 24 1998 61 69
42. C.M. Kessler, Z. Tang, and H.M. Jacobs The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction of mortality and morbidity Blood 89 1997 4393 4401
43. M. Uchiba, K. Okajima, and K. Murakami Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats Thromb Res 89 1998 233 241
44. B. Eisele, and M. Lamy Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure Semin Thromb Haemost 24 1998 71 80
45. J.A. Lorente, L.J. Garcia-Frade, and L. Landin Time course of hemostatic abnormalities in sepsis and its relation to outcome Chest 103 1993 1536 1542
46. M. Levi, and H. ten Cate Disseminated intravascular coagulation N Engl J Med 341 1999 586 592
47. S.M. Opal Phylogenetic and functional relationships between coagulation and the innate immune response Crit Care Med 28 Suppl. 9 2000 S77 S80
48. F. Fourrier, C. Chopin, J.J. Huart, I. Runge, C. Caron, and J. Goudemand Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation Chest 104 1993 882 888
49. D. Inthorn, J.N. Hoffmann, W.H. Hartl, D. Muehlbayer, and M. Jochum Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction Shock 8 1997 328 334
50. H.P. Schuster, B. Eisele, H.O. Keinecke, H. Heinrichs, A. Mescheder, and S. Knaub S-ATIII study: antithrombin III in patients with sepsis Intensive Care Med 24 Suppl 1 1998 76
51. B. Eisele, M. Lamy, and L.G. Thijs Antithrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis Intensive Care Med 24 1998 663 672
52. F. Baudo, T.M. Caimi, F. deCataldo, A. Ravizza, and S. Arlati Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study Intensive Care Med 24 1998 336 342
53. R. Balk, C. Bedrosian, L. McCormick, J. Baughman, B. Eisele, and H. Keinecke Prospective, double-blind, placebo-controlled, trial of ATIII substitution in sepsis Intensive Care Medicine 2 suppl 1995 517
54. B.L. Warren, A. Eid, and S.S. Pillay High-dose antithrombin III in severe sepsis: a randomized controlled trial JAMA 286 2001 1869 1878
55. W. Ilias, W. List, and J. Decruyenaere Antithrombin III in patients with severe sepsis: a pharmacokinetic study Intensive Care Med 26 2000 704 715
56. Wiedermann C.J., Hoffmann J.N., Ostermann H., et al. High dose antithrombin III in the treatment of severe sepsis with a high risk of death. European Society of Intensive Care Medicine meeting. Berlin, DE, Oct 11, 2004
57. S.M. Opal, S. Knaub, and H.-O. Keinecke Antithrombin III - where are we? 3rd Jena International Symposium on Sepsis and Multiorgan Dysfunction, Jena, Germany, 16 February, 2001 J Anasthesie und Intersivbehandlung 2 Suppl. 1 2001 Abstr. 46
58. S. LaRosa, and S.M. Opal Clinical trials of novel anticoagulants for severe sepsis: a tale of three molecules Advances in Sepsis 4 1 2004 17 23
59. D. Rublee, S.M. Opal, W. Schramm, H.-O. Keinecke, and S. Knaub Quality of life effects of AT III in sepsis survivors: results from the Kybersept trial Crit Care 6 2002 319 356
60. S.M. Opal Unintended bias, clinical trial results, and the post-randomization crossover fallacy Crit Care Med 32 3 2004 874 875
61. S.M. Opal, C.M. Kessler, J. Roemisch, and S. Knaub Antithrombin, heparin, and heparan sulfate Crit Care Med 30 5S 2002 325 332
62. S. Dunzendorfer, N. Kaneider, and A. Rabensteiner Cell-surface heparan sulfate proteoglycan-regulation of human neutrophil migration by the serpin antithrombin III Blood 97 4 2001 1079 1085
63. N.C. Kaneider, P. Egger, S. Dunzendorfer, and C.J. Weidermann Syndecan-4 as antithrombin receptor of human neutrophils Biochem Biophys Res Commun 287 2001 42 46
64. C. Oelschlager, J. Romisch, and A. Staubitz Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells Blood 99 11 2002 4015 4020
65. P.J. Souter, S. Thomas, and A.R. Hubbard Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood Crit Care Med 29 1 2001 134 139
66. J.N. Hoffmann, B. Vollmar, and M.W. Laschke Adverse effect on heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms Thromb Haemost 88 2002 242 252
67. J.N. Hoffman, D. Muhlbayer, M. Jochum, and D. Inthorn Effect of long-term and high-dose antithrombin supplemetnation on coagulation and fibrinolysis in patients with severe sepsis Crit Care Med 32 9 2004 1851 1859
68. T. Edmunds, S.M. VanPatten, and J. Pollock Transgenically produced human antithrombin:structural and functional comparison to human plasma-derived antithrombin Blood 91 1998 4561 4571
69. J.H. Levy, A. Weisinger, C.A. Ziomek, and Y. Echelard Recombinant antithrombin: production and role in cardiovascular disorder Semin Thromb Hemost 27 4 2001 405 416